Background: Response rate (RR) has been used as a defining endpoint of new-agent phase II trials for non-small-cell lung cancer (NSCLC). However, tumor responses to chemotherapy do not always result in prolonged survival of patients with this disease.
Introduction
Although cisplatin-based chemotherapy produced a modest benefit in the treatment of advanced non-smallcell lung cancer (NSCLC) over that of supportive care alone, new drug development is still required for further improvement of patient survival [1] . Phase II trials of new anticancer agents are designed to evaluate antitumor activity of the drugs in a specific disease. One of the currently-used defining endpoints of such trials is 'response rate (RR)', and investigators have considered it one of the most important parameters for determining whether further developmental trials of a drug are warranted [2, 3] . A higher RR in a trial involving NSCLC, however, does not always mean prolonged patient survival [4] . Thus, association between tumor response and meaningful clinical benefit such as patient survival should be validated. We investigated the association between RR and median survival time (MST) in singleagent phase II trials for NSCLC to reassess the endpoint and design of these trials.
Patients and methods
A MEDLINE search using two key words: lung cancer neoplasms/drug therapy in Medical Subject Headings (MeSH) and phase II in the period from 1976 to 1995 yielded 735 reports. They included 177 single-agent phase II trials and other trials involving small-cell lung cancer, modalities combined with radiotherapy or surgery and combination chemotherapy, phase I, I-II. Ill trials, and review articles. Of the 177 trials, one was excluded because the number of responders was not reported. Thus, 176 trials were the subject of the current study. They consisted of 166 single-arm trials and 10 randomized trials with two or more arms for each drug. In consequence, there were 183 separate treatment arms in 176 trials
The following data were obtained for each treatment arm: the name and class of the drug evaluated in the trial; the number of patients entered in the trial and the number of patients evaluable for a response; the number of responders (who showed a complete or partial response); RR; MST; and percentages of patients without distant metastasis, who had a performance status (PS) of 0-1, and who received prior chemotherapy. To evaluate the influence of age on these data, they were summarized in two groups according to the year the trial data were published: from 1976 to 1987 and from 1988 to 1995, because the median year of publication was 1988.
Associations between RR and the characteristics of the patients entered in the trial were investigated by a logistic regression model. The outcome variable was defined as RR, which was coded as 'zero' to indicate an RR of 20% or less, or '1' to indicate an RR of more than 20% in the treatment arm. The cut-off point of 20% was determined because a drug with a 20% or higher response rate has been considered active against non-small-cell lung cancer. Explanatory variables were percentage of patients without distant metastasis ( < 2 0 % or not reported (NR) versus 20% ^) , percentage of patients with PS 0-1 ( < 60%, median only or NR versus 60% $ ) , prior chemotherapy (no or NR versus yes), and year published (1976-1987 versus 1988-1995) . The codes for these variables were 'zero' or '1' for each treatment arm. As a rule, the cut-off points for continuous variables were selected so that treatment arms could be distributed as equally as possible between the groups. The correlation between MST and RR in trials published between 1988 and 1995 was shown in the scattergram. Pearson correlation coefficient (r) was calculated using the raw data of the two variables. We excluded trials published before 1988 because the tumor stage was reported in only 48% of them, detailed performance status in 44%, and MST in 16% (Table 2 ). To assess the influence of other variables, multiple linear regression analysis was performed. We included the following variables into the model as a continuous variable: RR, and percentages of patients without distant metastasis, with PS 0-1 and those who had received prior chemotherapy. The actual calculations were carried out using the STATISTICA (Stat-Soft) software system.
Results
A total of 79 drugs were identified, of which the most common classes were antimetabolites and alkylating agents (Table 1) . Recent trials have achieved higher patient homogeneity than older trials except in regard to tumor stage. Treatment arms in which 60% or more of the patients had performance status 0-1 accounted for 76% of the arms (74 of 97) in 1988-1995 but only 21% (18 of 86) before 1988. Treatment arms comprising patients both with and without prior chemotherapy accounted for 29% (28 of 97) in 1988-1995, but 69% (59/ 86) before 1988 ( Table 2) .
A total of 7423 patients had been entered in 183 arms of 176 trials, and 6768 (91%) were evaluable for response. Of these, a complete or partial response was obtained in 744 patients, for an overall RR of 11%. An RR of more than 20% was obtained in 26 treatment arms, most of which were published between 1988 and 1995 ( Table 2 ). The drugs which produced an RR of more than 20% were cisplatin [5] [6] [7] , epirubicin (given at a high dose) [8] , ifosfamide [9] , edatrexate [10] , irinotecan [11] , vinorelbine [12] , docetaxel [13, 14] , paclitaxel [15] , etoposide (given orally) [16] , vindesine [17] and 254-S [18] . Univariate analysis showed that tumor extent, PS, prior chemotherapy in patients registered in trials and the year the paper was published were associated with RR with statistical significance. Multivariate analysis showed that tumor extent, PS, and year of publication had elevated odds ratios, but wide confidence intervals (Table 3) . (15) 45 (52) 20 (23) 18 (21) 34 (40) 14 (16) 59 (69) 16 (19) 11 (13) 47 (55) 35 (41) 4(5) 13 (15) 1(1) 72 (84) 1988-1995 (n = 97) 33 (34) 53 (55) 11 (11) 7 (7) 74 (76) 12 (12) 4(4) 28 (29) 67 (69) 2 (2) 31 (32) 44 (45) 22 (23) 44 (45) 17 (18) 36 (37) Total (n = 183) 61 (33) 66 (36) 56 (31) 27 (15) 92 (50) 46 (25) 18 (10) 87 (48) 83 (45) 13 (7) 78 (43) 79 (43) 26 (14) 57 (31) 18 (10) 108(59) MST data were available for 75 arms. The number of arms with long MST (^8 months) increased with year of publication, from one (1%) in 1976-1987 to 17 (18%) in 1988-1995 (Table 2) . Twelve drugs yielded a long MST (Table 4) . Of these, seven drugs showed a high RR of more than 20% at least in one trial, whereas others did not. Three drugs, in particular, carboplatin, trimetrexate and fazarabine, yielded an MST of 8.6, 8.3, and 8.0 months, respectively, in at least one trial, but the RR in these trials were 6.5, zero, and zero %, respectively [19] [20] [21] . A significant correlation between RR and MST was obtained (r -0.504, P < 0.0001). However, a scattergram of the two parameters showed a wide range of MSTs at a given RR (Figure 1 ). This figure also shows that RR did not correlate with MST in randomized phase II trials (r = 0.471, P -0.14). The MST in these trials appeared, if anything, fairly constant at five to six months regardless of RR. Multiple linear regression analysis was performed in 46 treatment arms, because detailed data on patient characteristics were available in only these arms. RR had a significant correlation with MST (regression coefficient = 0.60, P -0.00003) after adjustment for other variables (Table 5) . Response rate (%) Figure 1 . Association between response rate and median survival time in trials published in 1988-1995 (n = 61 arms). Analysis including all trials showed a significant correlation between the two parameters (r = 0.504. P < 0.0001). In randomized trials, however, no correlation was obtained (r = 0.471, P = 0.14). Open circles, single arm trial; closed circles, randomized trial. 
Discussion
NSCLC is relatively resistant to cytotoxic agents. There were only five drugs in or before the 1980s that yielded an RR of more than 15% [22] . This study showed that the average RR in the 6768 patients evaluated in singleagent phase II trials was only 11%. In the 1990s, several new cytotoxic agents with an RR of more than 20% have been developed, including irinotecan, vinorelbine, docetaxel, paclitaxel, and 254-S. These drugs are now being evaluated in combination and are expected to alter the prognosis of advanced NSCLC. When interpreting the RR of a new anticancer agent in phase II trials, however, we should evaluate other factors together, especially those inherent to the patients, such as PS, extent of disease, recent weight loss, and history of prior chemotherapy, because RR may be modified by these factors obtained before the new anticancer agent was administered. Their influence on tumor response to chemotherapy has been investigated using individual patient data. That is, responses were compared between homogeneous subgroups of patients with and without a good prognostic factor [23, 24] . A trial, however, usually consists of patients with various prognostic factors in various percentages, and therefore RR is an integrated outcome from a heterogeneous population. Thus, the association between patient status and patient response could not always be applied to the relation between prognostic factors and RR in a trial. In this study, the associations between RR and the percentages of patients with these factors were analyzed. Although this is not a highly sensitive method, all prognostic factors examined here were associated with RR in the univariate analyses, and elevated odds ratios for disease extent and PS were observed in the multivariate analyses.
We identified 12 drugs associated with a prolonged MST of eight months or longer. Some of them produced a high RR of more than 30% in at least one trial, whereas others yielded no response in at least one trial. Of such drugs, carboplatin is widely used in the treatment for NSCLC [22] . The scattergram of RR and MST revealed a positive correlation between the two parameters, and the multivariate analysis showed that MST was significantly associated with RR after adjustment for other prognostic variables. However, a broad range of MSTs at a given RR level is still problematic when evaluating new cytotoxic agents for NSCLC. Although randomized allocation ensures comparability between intra-trial treatment arms but not between inter-trial arms, this measure is thought to work toward averaging known and unknown prognostic factors, resulting in a fall in RR within the generally accepted range of this parameter [2, 25] . Thus, we had hypothesized that the correlation between RR and MST would be better in randomized phase II trials. The current study, however, showed that no improvement in the correlation was obtained in these trials.
There are several reasons for dissociation between RR and MST. First, tumor responses may be inaccurate because of errors in tumor measurements, errors in selection of measurable targets and radiologic technical problems. A study comparing tumor responses as evaluated by investigators with those evaluated by an independent evaluation committee showed major discrepancies in 40% of the files reviewed [26] . Second, the subjects of phase II trials should be representative of a large population of patients with advanced NSCLC. Accruing only prognostically-good patients can result in a long MST regardless of the activity of the drug [27, 28] . Third, whether all patients or only evaluable patients are included in the analysis can also influence RR. Exclusions sometimes made for inevaluable patients who failed to complete chemotherapy or who are lost to follow-up can lead to biased results [27, 28] . Fourth, a 50% or more decrease in tumor area may involve only minimal killing of tumor cells, and thus not indicate a biologically significant reduction in tumor burden. In addition, a relatively short response duration (one month or longer) may be insufficient to significantly prolong survival [29] . Finally, drugs that stabilize disease without an objective response may slow tumor growth sufficiently to improve patient survival [29] . This requires consideration of tumor types, because stable disease has effects on survival equivalent to those of a partial response in relatively slow-growing tumors such as colorectal cancer but has no effect on survival in rapidly-growing tumors such as ovarian cancer [30] . In NSCLC, however, there is no reliable data on the impact of stable disease on patient survival, and further studies are needed.
The primary endpoint of Phase II trials has been RR, because tumor shrinkage was believed to be linked to the drug's biological activity and to lead to longer survival and/or decreased symptoms [2, 3] . We showed in this study that RR was correlated with MST, but there remains the long-standing concern that the apparently positive correlation between tumor response and increased survival is in part a reflection of the fact that patients who enjoy greater survival, in particular those who do not suffer an early death, have greater opportunity to respond. Thus, more refined endpoints of Phase II trials specific for NSCLC, which are more relevant and able to reliably predict true clinical efficacy, are necessary [32] . We should reconsider the definition of RR, especially the duration of response. A three-month or longer duration of response has been proposed instead of the current criterion of one month or longer [27, 31] . This criterion is practical because repeated computed tomography scans at four-week intervals are not possible in all hospitals [31] . A parameter that indicates patient survival directly, such as MST and the one-year survival rate, would provide additional information. The disadvantages of this parameter are the necessity of large patient samples and long periods to yield results, and the possible influence of effective secondary therapies [31, 32] . In metastatic NSCLC, however, MST is less than one year and there are no established salvage therapies. Another point to be considered when using survival data as one of the endpoints of phase II trials for NSCLC is that single-agent therapy is rarely expected to have an impact on survival [33] . Thus, this survival parameter would be a practical endpoint and contribute useful information if employed in combination with another endpoint, such as RR.
The major limitation of this study may be the selection of papers for our analysis. Since there is a tendency for studies with positive results to be preferentially published over those with negative results, it may be that fewer studies with a low RR have been published. Thus, the papers analyzed here may be biased toward those with a high RR. In addition, MST was not reported in the majority of trials selected for the current study, probably because the observation periods were too short to obtain MST in these trials. This may also have produced some bias because MST could be more frequently obtained in trials involving patients with a poorer prognosis.
In conclusion, a significant correlation between MST and RR was noted in single-agent phase II trials for NSCLC after adjustment for other variables, but there is still room for further consideration of the definition of RR and the use of another parameter that directly indicates patient survival.
